Larimar Therapeutics (LRMR) EBT (2013 - 2025)
Larimar Therapeutics (LRMR) posted EBT of -$65.5 million for Q4 2025, down 29.26% on a QoQ basis from -$50.7 million in Q3 2025, and up 67.93% year-over-year from -$39.0 million in Q4 2024.
Larimar Therapeutics (LRMR) EBT (2013 - 2025) Analysis & Trends
Larimar Therapeutics' EBT history runs 13 years deep, the most recent figure standing at -$65.5 million for Q4 2025.
- Quarterly EBT rose 67.93% year-over-year to -$65.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$182.4 million (up 37.55% YoY) and the FY2025 annual result came in at -$174.0 million, up 34.07% from the prior year.
- EBT was -$65.5 million for Q4 2025 at Larimar Therapeutics, down from -$50.7 million in the prior quarter.
- Across five years, EBT topped out at -$9.7 million in Q1 2023 and bottomed at -$204.3 million in Q4 2024.
- A 5-year average of -$52.6 million and a median of -$26.7 million in 2024 frame the typical range for EBT.
- Annual changes were most pronounced in 2024 — EBT sank 186.01% — and 2025, when it soared 67.93%.
- Larimar Therapeutics' EBT stood at -$133.1 million in 2021, then decreased by 6.14% to -$141.3 million in 2022, then retreated by 10.38% to -$155.9 million in 2023, then sank by 31.03% to -$204.3 million in 2024, then surged by 67.93% to -$65.5 million in 2025.
- Business Quant data shows LRMR's EBT at -$65.5 million in Q4 2025, -$50.7 million in Q3 2025, and -$29.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | -15.31 Mn |
| 4 | BeOne Medicines | 472.68 Bn | 467.89 Bn | 1.35 Bn | 259.22 Mn |
| 5 | Vertex Pharmaceuticals | 122.24 Bn | 114.99 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.33 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.93 Bn | 50.75 Bn | 1.41 Bn | 541.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Larimar Therapeutics | 36.67 Mn | -100.18 Mn | - | -65.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -65.52 Mn |
| Sep 30, 2025 | -50.69 Mn |
| Jun 30, 2025 | -28.98 Mn |
| Mar 31, 2025 | -37.24 Mn |
| Dec 31, 2024 | -204.32 Mn |
| Sep 30, 2024 | -25.66 Mn |
| Jun 30, 2024 | -34.40 Mn |
| Mar 31, 2024 | -27.73 Mn |
| Dec 31, 2023 | -155.93 Mn |
| Sep 30, 2023 | -17.60 Mn |
| Jun 30, 2023 | -16.62 Mn |
| Mar 31, 2023 | -9.70 Mn |
| Dec 31, 2022 | -141.27 Mn |
| Sep 30, 2022 | -10.86 Mn |
| Jun 30, 2022 | -11.18 Mn |
| Mar 31, 2022 | -17.39 Mn |
| Dec 31, 2021 | -133.10 Mn |
| Sep 30, 2021 | -19.69 Mn |
| Jun 30, 2021 | -21.94 Mn |
| Mar 31, 2021 | -21.80 Mn |